Search Results - "grellety, Thomas"

SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma by Laurent, Elodie, Begueret, Hugues, Bonhomme, Benjamin, Veillon, Rémi, Thumerel, Matthieu, Velasco, Valérie, Brouste, Véronique, Hoppe, Stéphanie, Fournier, Marion, Grellety, Thomas, MacGrogan, Gaëtan

“…Triple-negative breast cancer (TNBC) patients have an increased risk of developing visceral metastases and other primary nonbreast cancers, particularly lung…”
Get full text

Cancer du sein triple négatif exprimant le récepteur aux androgènes : de la biologie à la thérapeutique by Grellety, Thomas

Get full text

Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data by Rhanine, Yasmine, Bonnefoi, Hervé, Goncalves, Anthony, Debled, Marc, Le Moulec, Sylvestre, Bonichon, Nathalie, Macgrogan, Gaetan, Arnedos, Monica, Dubroca-Dehez, Bénédicte, Grellety, Thomas

“…Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit…”
Get full text

Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target by Grellety, Thomas, Callens, Celine, Richard, Elodie, Briaux, Adrien, Vélasco, Valérie, Pulido, Marina, Gonçalves, Anthony, Gestraud, Pierre, MacGrogan, Gaetan, Bonnefoi, Hervé, Cardinaud, Bruno

“…Our aim was to identify predictive factors of abiraterone acetate efficacy and putative new druggable targets in androgen receptor (AR)-positive…”
Get full text

Clinical impact of extensive molecular profiling in advanced cancer patients by Cousin, Sophie, Grellety, Thomas, Toulmonde, Maud, Auzanneau, Céline, Khalifa, Emmanuel, Laizet, Yec'han, Tran, Kevin, Le Moulec, Sylvestre, Floquet, Anne, Garbay, Delphine, Robert, Jacques, Hostein, Isabelle, Soubeyran, Isabelle, Italiano, Antoine

“…Previous precision medicine studies have investigated conventional molecular techniques and/or limited sets of gene alterations. The aim of this study was to…”
Get full text

PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53 by Grellety, Thomas, Laroche-Clary, Audrey, Chaire, Vanessa, Lagarde, Pauline, Chibon, Frñdñric, Neuville, Agnes, Italiano, Antoine

“…Background The aim of this study was to explore the efficacy and define mechanisms of action of PRIMA-1.sup.MET as a TP53 targeted therapy in soft-tissue…”
Get full text

Androgen receptor-positive triple negative breast cancer: From biology to therapy by Grellety, Thomas

“…A subgroup of androgen receptor-expressing tumors represents approximately 30 % of all triple negative tumors. The androgen receptor and its signaling pathways…”
Get more information

CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity by Meynard, Lucie, Grellety, Thomas

“…A 59-year-old woman presented with a bone-only metastatic luminal breast cancer. She received first-line treatment with aromatase inhibitors associated with a…”
Get more information

Encouraging Trends in Modern Phase 1 Oncology Trials by Chakiba, Camille, Grellety, Thomas, Bellera, Carine, Italiano, Antoine

“…Historically, phase 1 trials have been aimed at defining the toxic effects of an agent. With the advent of targeted therapies and immunotherapies, response…”
Get full text

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection by You, Benoit, Ravaud, Alain, Canivet, Anne, Ganem, Gérard, Giraud, Philippe, Guimbaud, Rosine, Kaluzinski, Laure, Krakowski, Ivan, Mayeur, Didier, Grellety, Thomas, Lotz, Jean-Pierre

“…On request of the French Health Ministry, the French High Council for Public health (Haut Conseil de Santé Publique [HCSP]) entrusted a representative group of…”
Get full text

Cancer du sein triple négatif exprimant le récepteur aux androgènes : de la biologie à la thérapeutique by Grellety, Thomas

“…La segmentation récente des cancers mammaires triple négatifs a permis de mettre en lumière un sous-groupe de cancers exprimant le récepteur aux androgènes. Ce…”
Get full text

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial by Toulmonde, Maud, Penel, Nicolas, Adam, Julien, Chevreau, Christine, Blay, Jean-Yves, Le Cesne, Axel, Bompas, Emmanuelle, Piperno-Neumann, Sophie, Cousin, Sophie, Grellety, Thomas, Ryckewaert, Thomas, Bessede, Alban, Ghiringhelli, François, Pulido, Marina, Italiano, Antoine

“…There is a strong rationale for treating sarcomas with immunotherapy. To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in…”
Get more information

Nouvelles AMM : trastuzumab-deruxtecan – cancer du sein métastatique HER2-faible by Gorgeu, Violaine, Grellety, Thomas

Get full text

Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer by Grellety, Thomas, Hajjaji, Nawale, Petit, Thierry, Bailleux, Caroline

“…HR+ breast cancers are defined by the prominence of signaling pathways dependent on the estrogen receptor. Endocrine therapy is the standard treatment for…”
Get more information

Real-life data of antiandrogens (AA) use in metastatic androgen receptor positive triple negative breast cancer (AR+ TNBC): The ATOVAT retrospective French cohort by Rhanine, Yasmine, Bonnefoi, Herve R., Goncalves, Anthony, Debled, Marc, Le Moulec, Sylvestre, Bonichon-Lamichhane, Nathalie, Dubroca-Dehez, Benedicte, Grellety, Thomas

“…e13074 Background: AR+ TNBC account for around 25% of all TNBC. Identification of those patients is difficult since AR expression (IHC) testing is not…”
Get full text

Encouraging Trends in Modern Phase 1 Oncology Trials: Letter by Chakiba, Camille, Grellety, Thomas, Bellera, Carine, Italiano, Antoine

“…Historically, phase 1 trials have been aimed at defining the toxic effects of an agent. With the advent of targeted therapies and immunotherapies, response…”
Get full text

Angiosarcoma associated with a Kasabach-Merritt syndrome: report of two cases treated with paclitaxel by Grellety, Thomas, Italiano, Antoine

“…Angiosarcomas are rare, aggressive vascular malignancies of endothelial cell differentiation. Kasabach-Merritt syndrome is a rare condition defined by the…”
Get more information

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours by Richard, Elodie, Grellety, Thomas, Velasco, Valerie, MacGrogan, Gaetan, Bonnefoi, Hervé, Iggo, Richard

“…There is a paucity of models for hormone receptor‐positive (HR+) breast cancer because of the difficulty of establishing xenografts from these tumours. We show…”
Get full text

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum by Leary, Alexandra, Gladieff, Laurence, Sabatier, Renaud, Paoletti, Xavier, Marmé, Frederik, Van Gorp, Toon, Alexandre, Jerome, Grellety, Thomas, Angelergues, Antoine, Simmet, Victor, Grenier, Julien, Augereau, Paule, Fabbro, Michel, Combe, Pierre, Hardy-Bessard, Anne-Claire, Kaczmarek, Emilie

“…TPS5618 Background: Besides PARP inhibitors and bevacizumab, there are no approved maintenance therapies after platinum based chemotherapy for patients with a…”
Get full text

Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1 by Lafon, Mathilde, Blaye, Celine, Kind, Michele, Bechade, Dominique, Chassaigne, Florence, Italiano, Antoine, Grellety, Thomas

“…We report the first case of sarcoidosis-like reaction in a patient treated by anti-PD-L1 for a breast cancer. A 69-year-old woman presented with a…”
Get more information